Ask about this productRelated genes to: IMPDH2 antibody
- Gene:
- IMPDH2 NIH gene
- Name:
- inosine monophosphate dehydrogenase 2
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 3p21.31
- Locus Type:
- gene with protein product
- Date approved:
- 1992-12-08
- Date modifiied:
- 2016-10-05
Related products to: IMPDH2 antibody
Related articles to: IMPDH2 antibody
- Brain metastases (BM) occur in 26% of cancer patients and have a 90% mortality rate within 1 y of diagnosis, yet the current standard of care remains palliative. We have previously shown that de novo GTP synthesis is a druggable metabolic vulnerability in BM cells, through its rate-limiting enzyme, inosine monophosphate dehydrogenase (IMPDH). IMPDH inhibitors have progressed to phase-II oncology trials in the past, failing largely due to dose-limiting toxicities associated with off-target inhibition of IMPDH1, the constitutively expressed isoenzyme in normal human lymphocytes. Here, we determined that a single subtype (isoenzyme) of IMPDH, IMPDH2, is specifically upregulated in brain metastasis-initiating cells (BMICs), absent in normal brain tissue, and is sufficient to drive the formation of BM. Moreover, we show that genetic knockout of IMPDH2 stops the proliferation of BM cells in vitro and the onset of BM in vivo. We synthesized IMPDH2-selective compounds and showed that they maintain a potent antiproliferation effect on BMICs, but spare immune cell function compared to previously developed pan-IMPDH inhibitors. Furthermore, we introduce a positive correlation between compound selectivity for IMPDH2 and the ability to synergize with Osimertinib: the standard of care for EGFR-mutant non-small cell lung cancer. Overall, our results suggest that specifically blocking IMPDH2 is an effective therapeutic strategy for BM by overcoming the immune suppressive effects that have hindered the clinical development of pan-IMPDH inhibitors in the past. An IMPDH2 specific therapy could be coadministered with primary tumor standard of care treatments to provide a safe and interceptional approach for BM. - Source: PubMed
Publication date: 2026/06/17
Kieliszek Agata MApel ErikaZheng SukyPiotrowski MathewChui DannyAlazet SébastienShamsi SaeidehMobilio DanielJohnson Jarrod WEscudero LauraVandevoorde KurtMei LinAcevedo MarianaSabbatani JulietteKent Oliver ADordahan FatemehYadav ArunMacKay BruceLeguay KevinBerger Kathleen JMiletic PetarZhai KuiAng PatrickHuebner ArianaChafe Shawn CSturino ClaudioSzychowski JanekVenugopal ChitraMancini JosephPhinney Amie LMagolan JakobSingh Sheila K - Prostate Cancer (PCa) is the most common male malignancy, and its initiation and progression may be influenced by environmental pollutants such as di(2-ethylhexyl) phthalate (DEHP). - Source: PubMed
Publication date: 2026/06/12
Chen JinjiChen JianlinHuang JunmingChen ShaohuaFeng Guanzheng - Kidney transplant recipients are at risk for Pneumocystis jirovecii pneumonia (PJP), particularly under profound immunosuppression. Mycophenolic acid (MPA) is widely used after transplantation and is associated with interindividual variability in exposure and hematologic toxicity. Genetic variation affecting MPA metabolism and pharmacodynamics may contribute to lymphopenia and PJP. - Source: PubMed
Publication date: 2026/06/03
Henskens NathalieLagrou Katriende Loor HenrietteCuypers LizeKuypers Dirk - Glioblastoma (GBM) is the most common and malignant primary brain tumor. Glioblastoma stem cells (GSCs) promote radioresistance and therapeutic failure, yet the underlying mechanisms remain unclear. Here, we show that heat shock protein HSPA6 promotes GSC radioresistance by enhancing GTP synthesis. HSPA6 is induced by irradiation and reduces GSC sensitivity to radiotherapy. HSPA6 interacts with and activates IMPDH2, a key rate-limiting enzyme in purine biosynthesis, thereby promoting GTP synthesis, reducing DNA damage, and enhancing radioresistance. Mechanistically, HSPA6 recruits ROCK2 to phosphorylate and activate IMPDH2 at S416. Pharmacological inhibition of HSPA6 and IMPDH2 combined with irradiation significantly improves survival in mice bearing GBM. Our study uncovers the crucial role of HSPA6/IMPDH2-mediated GTP synthesis in GSC radioresistance and suggests that targeting this axis may improve radiotherapy efficacy for GBM. - Source: PubMed
Publication date: 2026/06/02
Yang JunleiLin QiankunGu DanlingGao JianchengLiu YangYang KailinZhu ZheLu ChenfeiLi DaqiCi ShushengLin FanWang QianghuQian XuYou YongpingZhou QigangWang XiuxingLu MingZhang QianChen YunTao WeiweiZhang Junxia - Grape seed proanthocyanidin extract (GSPE), derived from Vitis vinifera L., has been used in traditional European and Mediterranean medicine to treat inflammation, vascular diseases, and wounds. Historically employed for "detoxification" and "hard lumps" (possibly tumors), its effects are now attributed to GSPE's antioxidant and antiproliferative properties. Modern studies suggest these mechanisms may underlie its potential anticancer applications, including against bladder cancer. - Source: PubMed
Publication date: 2026/04/08
Han XiangDong ShuhongWang YingwenFang XingqiGu MengLi XiuyaWu YongjieZhang Baolai